In AML with NPM1 mutations, NPM1–FOXM1 complex sequesters FOXM1 in the cytoplasm and confers favorable treatment outcomes for AML patients because of FOXM1 inactivation. This evidence concerns the gene FOXM1 and acute myeloid leukemia.